Next Article in Journal / Special Issue
Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients
Previous Article in Journal
Bridging the B Cell Gap: Novel Technologies to Study Antigen-Specific Human B Cell Responses
Previous Article in Special Issue
Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart
Article

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events

1
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, PS 11528 Athens, Greece
2
Hematology Laboratory-Blood Bank, Aretaieio Hospital, School of Medicine, National and Kapodistrian University of Athens, PS 11528 Athens, Greece
3
Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, PS 15784 Athens, Greece
4
Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, PS 15784 Athens, Greece
*
Author to whom correspondence should be addressed.
Equal contribution as first authors.
Academic Editor: Luis Martinez-Sobrido
Vaccines 2021, 9(7), 712; https://doi.org/10.3390/vaccines9070712
Received: 24 May 2021 / Revised: 15 June 2021 / Accepted: 21 June 2021 / Published: 1 July 2021
(This article belongs to the Special Issue SARS-CoV-2 Serological Studies around the Globe)
It is unclear whether the ChAdOx1 nCov-19 vaccine can induce the development of anti-PF4 antibodies in vaccinated individuals who have not developed thrombosis. The aim of this prospective study was to evaluate the presence of antibodies against heparin/PF4 in adults who received a first dose of the ChAdOx1 nCov-19 vaccine, and correlate them with clinical data and antibody responses to the vaccine. We detected non-platelet activating anti-PF4 antibodies in 67% (29/43) of the vaccinated individuals on day 22 following the first dose of the ChAdOx1 nCov-19 vaccine, though these were detected in low titers. Furthermore, there was no correlation between the presence of anti-PF4 IgG antibodies and the baseline clinical characteristics of the patients. Our findings suggest that the ChAdOx1 nCov-19 vaccine can elicit anti-PF4 antibody production even in recipients without a clinical manifestation of thrombosis. The presence of anti-PF4 antibodies was not sufficient to provoke clinically evident thrombosis. Our results offer an important insight into the ongoing investigations regarding the underlying multifactorial pathophysiology of thrombotic events induced by the ChAdOx1 nCov-19 vaccine. View Full-Text
Keywords: SARS-CoV-2; COVID-19; ChAdOx1 nCov-19; anti-PF4; antibodies; vaccine; thrombosis SARS-CoV-2; COVID-19; ChAdOx1 nCov-19; anti-PF4; antibodies; vaccine; thrombosis
Show Figures

Figure 1

MDPI and ACS Style

Terpos, E.; Politou, M.; Ntanasis-Stathopoulos, I.; Karalis, V.; Merkouri, E.; Fotiou, D.; Gavriatopoulou, M.; Malandrakis, P.; Kastritis, E.; Trougakos, I.P.; Dimopoulos, M.A. High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. Vaccines 2021, 9, 712. https://doi.org/10.3390/vaccines9070712

AMA Style

Terpos E, Politou M, Ntanasis-Stathopoulos I, Karalis V, Merkouri E, Fotiou D, Gavriatopoulou M, Malandrakis P, Kastritis E, Trougakos IP, Dimopoulos MA. High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. Vaccines. 2021; 9(7):712. https://doi.org/10.3390/vaccines9070712

Chicago/Turabian Style

Terpos, Evangelos, Marianna Politou, Ioannis Ntanasis-Stathopoulos, Vangelis Karalis, Efrosyni Merkouri, Despina Fotiou, Maria Gavriatopoulou, Panagiotis Malandrakis, Efstathios Kastritis, Ioannis P. Trougakos, and Meletios A. Dimopoulos 2021. "High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events" Vaccines 9, no. 7: 712. https://doi.org/10.3390/vaccines9070712

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop